Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹32,600 Cr, it ranks #266 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 63 in Pharmaceuticals. At ₹244.23 (as of 16 Nov 2026), the share price is 2.5% below its 52-week high of ₹250.40 and 84.6% above its 52-week low of ₹132.30. The share price is up 22.8% over one year and up 15.0% over three months.
| Current Price | ₹244.23 |
|---|---|
| Market Cap | ₹32,600 Cr |
| NSE Symbol | PPLPHARMA |
| BSE Code | 543635 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -4.00% |
| Return on Assets | 0.36% |
| 52-Week Range | ₹132.30 – ₹250.40 |
| 1-Year Price Change | +22.8% |
| 3-Month Price Change | +15.0% |
| Beta (1Y) | 0.3 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.piramalpharma.com |
| Revenue | ₹2,617 Cr |
|---|---|
| Net Profit | ₹5 Cr |
| Net Margin | 0.2% |
| EPS (Basic) | ₹0.04 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Piramal Pharma Ltd reported revenue of ₹2,617 Cr in Q2 FY27, up 28.1% from ₹2,044 Cr in Q2 FY26 and up 15.3% from ₹2,270 Cr in Q1 FY27. It posted a net profit of ₹5 Cr for the quarter, against a net loss of ₹99 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,934 Cr (Q1 FY26) to ₹2,754 Cr (Q4 FY25). The company reported a net loss in 5 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,617 Cr | ₹5 Cr | 0.2% |
| Q1 FY27 | ₹2,270 Cr | −₹69 Cr | −3.1% |
| Q4 FY26 | ₹2,752 Cr | −₹9 Cr | −0.3% |
| Q3 FY26 | ₹2,140 Cr | −₹136 Cr | −6.4% |
| Q2 FY26 | ₹2,044 Cr | −₹99 Cr | −4.9% |
| Q1 FY26 | ₹1,934 Cr | −₹82 Cr | −4.2% |
| Q4 FY25 | ₹2,754 Cr | ₹154 Cr | 5.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 34.80% of Piramal Pharma Ltd's shares as of Sept 2026, against 34.86% in Sept 2025 (−0.06 percentage points). Delivery averaged 38.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
1. Pharma-This segment engages in the pharmaceuticals business. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharma-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Piramal Pharma Ltd is trading at ₹244.23, with a market capitalisation of ₹32,600 Cr.
Piramal Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Piramal Pharma Ltd has a return on equity of -4.00%.
Piramal Pharma Ltd is listed on the NSE under the symbol PPLPHARMA and on the BSE under the scrip code 543635.
Piramal Pharma Ltd's share price is up 22.8% over one year and up 15.0% over three months. Its 52-week range is ₹132.30 to ₹250.40.
In Q2 FY27, Piramal Pharma Ltd reported revenue of ₹2,617 Cr and net profit of ₹5 Cr, with basic EPS of ₹0.04 (consolidated, parsed from the company's exchange filing).
Piramal Pharma Ltd reported revenue of ₹2,617 Cr in Q2 FY27, up 28.1% from ₹2,044 Cr in Q2 FY26 and up 15.3% from ₹2,270 Cr in Q1 FY27.
Promoters held 34.80% of Piramal Pharma Ltd's shares as of Sept 2026, against 34.86% in Sept 2025 (−0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.